162740-03-6

Basic information

• Product Name: (2-isopropyl-1,3-oxazol-4-yl)methanol(SALTDATA: FREE)
• Synonyms: (2-isopropyl-1,3-oxazol-4-yl)methanol(SALTDATA: FREE);(2-isopropyl-1,3-oxazol-4-yl)methanol
• CAS NO: 162740-03-6
• Molecular Formula: C7H11NO2
• Molecular Weight: 141.16774
• Mol File: 162740-03-6.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (2-isopropyl-1,3-oxazol-4-yl)methanol(SALTDATA: FREE)(CAS DataBase Reference)
• NIST Chemistry Reference: (2-isopropyl-1,3-oxazol-4-yl)methanol(SALTDATA: FREE)(162740-03-6)
• EPA Substance Registry System: (2-isopropyl-1,3-oxazol-4-yl)methanol(SALTDATA: FREE)(162740-03-6)

Safety Data

• Hazardous Substances Data: 162740-03-6(Hazardous Substances Data)

Usage

General Description

The chemical (2-isopropyl-1,3-oxazol-4-yl)methanol, also known as SALTDATA: FREE, is a compound that belongs to the class of oxazoles. It is a white crystalline solid that is mainly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. The compound has potential biological activity and can be used as a building block for the preparation of various biologically active molecules. It is important to handle (2-isopropyl-1,3-oxazol-4-yl)methanol with caution, as it may have hazards associated with its handling and use.

Upstream product

• 162740-05-8 N-isobutyryl-L-serine methyl ester 
• 162739-76-6 methyl (4S)-4,5-dihydro-2-(1-methylethyl)oxazole-4-carboxylate 
• 155884-24-5 methyl 2-isopropyl-2-oxazole-4-carboxylate 

Relevant articles and documents

Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacy

The structure-activity studies leading to the potent and clinically efficacious HIV protease inhibitor ritonavir are described. Beginning with the moderately potent and orally bioavailable inhibitor A-80987, systematic investigation of peripheral (P3 and P2') heterocyclic groups designed to decrease the rate of hepatic metabolism provided analogues with improved pharmacokinetic properties after oral dosing in rats. Replacement of pyridyl groups with thiazoles provided increased chemical stability toward oxidation while maintaining sufficient aqueous solubility for oral absorption. Optimization of hydrophobic interactions with the HIV protease active site produced ritonavir, with excellent in vitro potency (EC50 = 0.02 μM) and high and sustained plasma concentrations after oral administration in four species. Details of the discovery and preclinical development of ritonavir are described.